Piers E M Patten
Overview
Explore the profile of Piers E M Patten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Friedman D, Mehtani D, Vidler J, Patten P, Hoogeboom R
Hemasphere
. 2024 Dec;
8(12):e70064.
PMID: 39691453
Chronic lymphocytic leukemia (CLL) is an incurable progressive malignancy of CD5 B cells with a birth rate between 0.1% and 1% of the entire clone per day. However, the phenotype...
2.
Al-Agil M, Obee S, Dinu V, Teo J, Brawand D, Patten P, et al.
BMC Med Inform Decis Mak
. 2024 Sep;
24(1):255.
PMID: 39285367
Background: The aim is to develop and deploy an automated clinical alert system to enhance patient care and streamline healthcare operations. Structured and unstructured data from multiple sources are used...
3.
Bourlon C, Roddie C, Menne T, Norman J, OReilly M, Gibb A, et al.
Haematologica
. 2024 Apr;
109(8):2716-2720.
PMID: 38572567
No abstract available.
4.
Dreyling M, Fowler N, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, et al.
Blood
. 2024 Jan;
143(17):1713-1725.
PMID: 38194692
Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the third- or later-line setting. The primary analysis (median follow-up, 17 months) of the phase 2 ELARA trial...
5.
Munir T, Cairns D, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al.
N Engl J Med
. 2023 Dec;
390(4):326-337.
PMID: 38078508
Background: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment...
6.
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al.
Lancet Oncol
. 2023 May;
24(5):535-552.
PMID: 37142374
Background: The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients...
7.
Kakkassery H, Carpenter E, Patten P, Irshad S
Trends Mol Med
. 2022 Aug;
28(12):1082-1099.
PMID: 35999131
Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer patients than on the general population. Approved vaccines for use...
8.
Salles G, Schuster S, Dreyling M, Fischer L, Kuruvilla J, Patten P, et al.
Blood Adv
. 2022 Aug;
6(22):5835-5843.
PMID: 35973192
The ELARA trial indicates tisagenlecleucel (tisa-cel) is an effective anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory follicular lymphoma (r/r FL). As ELARA is a single-arm trial, this...
9.
Salles G, Schuster S, Fischer L, Kuruvilla J, Patten P, von Tresckow B, et al.
Hemasphere
. 2022 Jul;
6(7):e745.
PMID: 35813099
This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and...
10.
Kuhnl A, Roddie C, Kirkwood A, Tholouli E, Menne T, Patel A, et al.
Br J Haematol
. 2022 Apr;
198(3):492-502.
PMID: 35485402
CD19 CAR-T have emerged as a new standard treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL). CAR-T real-world (RW) outcomes published to date suggest significant variability across countries. We provide...